Women at high bleeding risk (HBR) do not seem to experience more ischemic or bleeding events than men and may especially benefit from a regimen of short dual antiplatelet therapy (DAPT) after PCI, ...

Among patients receiving PCI with a third-generation DES with ultrathin struts and advanced polymer technology, 3 months of dual antiplatelet therapy (DAPT) is noninferior to 12 months in terms of net ...

Select high bleeding risk (HBR) patients can safely receive just 1 or 3 months of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) without more ischemic events, ...

A short-term course of dual antiplatelet therapy (DAPT) is non-inferior to a longer course in patients who have undergone placement of a particular kind of drug-eluting stent (DES), researchers ...

In acute coronary syndrome (ACS), a prasugrel (Effient)-based antiplatelet regimen passed muster for reducing bleeding without compromising ischemic protection after percutaneous coronary intervention ...

Please provide your email address to receive an email when new articles are posted on . For adults who undergo PCI with a drug-eluting stent, recommendations for dual antiplatelet therapy have evolved ...

While dual antiplatelet therapy (DAPT) has long been the standard of care for the management of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), there is an ...

The first four patients were enrolled by (Professor Barbara Stähli and her team at the University Hospital of Zurich in Switzerland initiating the much awaited RCT which will assess the different ...

SAN FRANCISCO -- For ticagrelor-based antithrombotic regimens after drug-eluting stent implantation for acute coronary syndrome (ACS), stopping aspirin within the first month appeared to be safer than ...

The first ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease is published online today in European Heart Journal, and on the ESC website. The document was developed in ...